Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention.
March 23, 2021: “New results from the STEP phase 3a clinical trial programme demonstrated weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo.
In the STEP 4 trial, study participants who reached the maintenance dose of semaglutide 2.4 mg during a 20-week run-in period were randomised to either continue treatment with semaglutide 2.4 mg or switch to placebo for 48 weeks.
The full results of the STEP 4 trial were presented today at the virtual Endocrine Society (ENDO) 2021 Annual Meeting and published in the Journal of the American Medical Association.
“For people with obesity, maintaining weight loss in the long term is challenging as both physiological and hormonal changes that occur following an initial weight loss can lead to weight regain.
These changes, known as metabolic adaptation, result in lasting increased levels of hunger and desire to eat while reducing energy expenditure,” said Dr Domenica Rubino, lead investigator of the STEP 4 trial and Director of Washington Center for Weight Management and Research.
“Like any other chronic disease, obesity requires a long-term, individualised approach to care, inclusive of medication and lifestyle components.”
Following the 20-week run-in period, people who continued treatment with semaglutide 2.4 mg for an additional 48 weeks continued to lose weight with a statistically significant additional mean weight loss of 7.9% (8.8% for the trial product estimand) from week 20 to week 68. People who were switched to placebo following the 20-week run-in period regained 6.9% of their body weight from week 20 to 68 (6.5% for the trial product estimand).
The estimated treatment difference [ETD] for the treatment policy estimand was -14.8% (95% confidence interval [CI]: -16.0, -13.5; p<0.0001).
People who stayed on semaglutide 2.4 mg throughout the entire 68-week trial achieved a total weight loss of 17.4% (1) (18.2% for the trial product estimand).
Both treatment groups followed a reduced-calorie diet and increased physical activity programme throughout the study.
“Obesity is a chronic disease that requires ongoing management and the results from STEP 4 trial strengthens the evidence around the potential of semaglutide 2.4 mg to transform the medical management of obesity,” said Martin Holst Lange, executive vice president, Development at Novo Nordisk.
“Millions of people living with obesity are in need of additional treatment options to help them lose weight and keep it off.
The results from STEP 4 show that to sustain weight loss it is important to maintain treatment and that semaglutide 2.4 mg has the potential to offer sustained weight loss of more than 17% after 68 weeks of treatment.”
The semaglutide 2.4 mg safety profile is in line with observations seen previously with GLP-1 receptor agonists.
It is generally well-tolerated, and the most common adverse events among people treated with semaglutide 2.4 mg were gastrointestinal events.
About STEP 4 and the STEP clinical trial programme
STEP 4 was a 68-week phase 3a randomised, double-blind, multicentre, placebo-controlled trial that compared the safety and efficacy of once-weekly subcutaneous semaglutide 2.4 mg versus placebo on change in body weight.
The trial was designed to assess the effect of continuing versus discontinuing semaglutide 2.4 mg in adults with obesity (BMI 30 kg/m2), or overweight (BMI 27 kg/m2) with at least one weight-related comorbidity and without type 2 diabetes (HbA1c <6.5%).
During the 20-week run-in period (Week 0 to Week 20), participants were treated with semaglutide (16 weeks escalation, followed by 4 weeks at the target dose) as an adjunct to lifestyle intervention (–500 kcal/day diet together with 150 minutes/week of physical activity).
Following the run-in period, the 803 people who reached the maintenance dose of semaglutide (2.4 mg) reduced their mean body weight from 107.2 kg (Week 0) to 96.1 kg (Week 20) and were randomised (in a 2:1 ratio) to continue treatment with semaglutide 2.4 mg or switch to placebo for a further 48 weeks (Week 20 to Week 68) with lifestyle intervention.
The primary endpoint of the trial was the percentage change in body weight from randomisation (Week 20) to the end of treatment (Week 68).
Confirmatory secondary endpoints included change in waist circumference, systolic blood pressure, and physical functioning score on the 36-item Short Form Survey (SF-36), assessed from randomisation (Week 20) to the end of treatment (Week 68).
Supportive secondary endpoints included percent change in body weight from baseline (Week 0) to the end of treatment (Week 68).2
STEP (Semaglutide Treatment Effect in People with obesity) is a phase 3 clinical development programme with once-weekly subcutaneous semaglutide 2.4 mg in obesity.
The global clinical phase 3a programme consists of four trials and has enrolled approximately 4,500 adults with overweight or obesity.3
About subcutaneous semaglutide 2.4 mg for weight management
Once-weekly semaglutide 2.4 mg is under investigation for chronic weight management and not yet approved for people with obesity.
It is currently under regulatory review in several countries, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Semaglutide is an analogue of the human glucagon-like peptide-1 (GLP-1) hormone, with 94% similarity to the native human GLP-1 molecule.
It induces weight loss by reducing hunger, increasing feelings of fullness and thereby helping people eat less and reduce their food cravings.”
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=51957
